"In fact, Poland has some of the lowest access of innovative drugs in the EU within the oncology field, considerably less than Germany and the UK."
In Conversation
"Our main goal is to be perceived as the leading partner for ophthalmologists, in their daily practice, driving innovation and education forward."
"We are working to ensure market access to our newest breast cancer treatments, that are not accessible to Polish patients."
"Galderma Poland is very strong in Rx and has been our core business for years, achieving still double-digit growth in 2017, a challenging task considering the…
"There is an overwhelming need in Poland for well-structured and positioned R&D companies with balanced risk run by people with a successful track record – such…
"Poland does not reimburse innovative drugs to a large extent, and this is a dominant reason why it is important to explain thoroughly the peculiarities of…
"Within human reproduction, our Polish sales and marketing team is in close contact with all IVF clinicians and gynaecologists, and there are plans to conduct local…
"Looking ahead, Mylan observes an outstanding opportunity in the field of biosimilars, and this area is set to develop massively."
"We are running a campaign called “Go to brand”, where we promote the Polish producer abroad in conferences and in general within Poland, compared to many…
"Poland is now much more exposed to senior management and we are perceived as a priority market for Chiesi."
"We have built our position here step by step, going from being Mr. Nobody in Poland to having a strong presence in gastroenterology, oncology and now,…
"We will be constantly involved in rising awareness about diseases underlying that early treatment is beneficial for patients and for the system."
